Insulet (United States)
PODD
$134.68
-2.35%
Insulet Corporation is a medical device company specializing in tubeless insulin pump technology for diabetes management, with its flagship Omnipod system offering a smartphone-controlled, wearable insulin delivery solution. As a pioneer and market leader in the patch pump segment, Insulet has differentiated itself through its innovative, user-friendly design that has attracted over 600,000 patients worldwide. The company is currently navigating a critical juncture marked by a high-risk FDA recall of its Omnipod 5 pods due to insulin delivery concerns, which has overshadowed its robust revenue growth and raised questions about product safety, brand reputation, and future financial performance.…
PODD
Insulet (United States)
$134.68
Related headlines
Investment Opinion: Should I buy PODD Today?
Rating: Hold. The stock is a high-risk turnaround play with a mixed outlook. Analyst consensus is neutral, with an average target of $171.91, implying modest upside. The thesis hinges on the company's ability to navigate the FDA recall and restore investor confidence. Given the severe price decline and unresolved regulatory issues, a cautious stance is warranted.
Sign up to view all
PODD 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The company's strong revenue growth and reasonable forward valuation are offset by the severe regulatory overhang and negative price momentum. The wide gap between trailing and forward PE suggests the market expects a sharp earnings recovery, which is uncertain. A resolution of the recall could trigger a rally, while any negative development could push the stock lower. Upgrading to bullish would require clear evidence of recall resolution and sustained growth; downgrading to bearish would follow further regulatory actions or market share losses.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insulet (United States)'s 12-month outlook, with a consensus price target around $171.91 and implied upside of +27.6% versus the current price.
Average Target
$171.91
0 analysts
Implied Upside
+27.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$144 - $275
Analyst target range
The wide target range, from a low of $144.00 to a high of $275.00, reflects the high uncertainty surrounding Insulet's future. The low target likely prices in prolonged negative impacts from the FDA recall, including potential market share loss and increased regulatory scrutiny, while the high target assumes a swift resolution and a return to strong growth driven by the Omnipod platform's expansion. Recent institutional ratings show no downgrades, with firms maintaining their positive stances, which may signal confidence in the company's ability to navigate the recall, but the stock's significant underperformance relative to the market (relative strength of -76.1% over 1 year) suggests that investors remain cautious.
Bulls vs Bears: PODD Investment Factors
Insulet presents a classic high-risk, high-reward scenario. The bull case rests on strong revenue growth, high margins, and a reasonable forward valuation, while the bear case is dominated by the FDA recall's potential to damage brand trust and market position. Currently, the bearish evidence is stronger given the stock's severe underperformance and the unresolved regulatory issue. The most critical tension is whether the recall will be a temporary setback or a lasting competitive disadvantage. If Insulet swiftly resolves the recall and maintains growth, the stock could recover; otherwise, it may continue to decline.
Bullish
- Robust Revenue Growth: Q1 2026 revenue surged 33.9% YoY to $761.7M, accelerating from 8.9% growth in Q2 2025. This demonstrates strong demand for Omnipod products despite the recall.
- High Gross Margin: Gross margin stands at 71.6%, reflecting a highly profitable product line. This provides a buffer to absorb recall-related costs and supports long-term profitability.
- Positive Net Income: Trailing net income is $91.1M with a net margin of 9.1%, showing the company is profitable. This financial stability helps fund remediation efforts and R&D.
- Analyst Confidence: Despite the recall, no analyst downgrades have occurred, and the average target price of $171.91 implies ~16.6% upside from the current price. This suggests analysts view the recall as manageable.
Bearish
- High-Risk FDA Recall: The FDA flagged a high-risk recall of Omnipod 5 pods due to insulin under-delivery, which can cause serious health risks. This poses significant reputational damage and potential market share loss.
- Severe Stock Decline: The stock is down 57.4% over the past year and 37.8% over six months, trading near its 52-week low. This reflects deep investor pessimism and a broken downtrend.
- High Trailing PE: Trailing PE is 81.0x, indicating that current earnings are low relative to price. This leaves the stock vulnerable to further de-rating if earnings disappoint.
- Negative Relative Strength: Relative strength over 1 year is -76.1%, meaning the stock has massively underperformed the market. This suggests persistent selling pressure and lack of buyer interest.
PODD Technical Analysis
Insulet's stock is in a pronounced downtrend, with a 1-year price change of -57.4% and a 6-month decline of -37.8%. The current price of $147.48 sits at only 8.6% above its 52-week low of $126.40 and 58.4% below its 52-week high of $354.88, indicating that the stock is trading near the bottom of its range. This positioning suggests that the market is pricing in significant negative sentiment, likely driven by the FDA recall and competitive pressures, rather than a value opportunity, as the downward momentum remains intact.
Beta
1.08
1.08x market volatility
Max Drawdown
-62.2%
Largest decline past year
52-Week Range
$126-$355
Price range past year
Annual Return
-60.1%
Cumulative gain past year
| Period | PODD Return | S&P 500 |
|---|---|---|
| 1m | -6.9% | -1.6% |
| 3m | -10.0% | +2.2% |
| 6m | -38.7% | +14.4% |
| 1y | -60.1% | +16.2% |
| ytd | -52.4% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PODD Fundamental Analysis
Insulet's revenue growth has been robust, with Q1 2026 revenue of $761.7 million representing a 33.9% year-over-year increase, accelerating from the 8.9% growth seen in Q2 2025. The company's revenue trajectory has been consistently upward, with sequential growth from $569.0 million in Q1 2025 to $783.8 million in Q4 2025, indicating strong demand for its Omnipod products. However, the recent FDA recall could impact future sales growth, as the company addresses product safety concerns and potential reputational damage.
Quarterly Revenue
$761700000.0B
2026-03
Revenue YoY Growth
+33.9%
YoY Comparison
Gross Margin
69.5%
Latest Quarter
Free Cash Flow
$412200000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PODD Overvalued?
Given that Insulet is profitable with a trailing net income of $91.1 million, the PE ratio is the most appropriate valuation metric. The trailing PE stands at 81.0x, while the forward PE is 19.1x, implying that the market expects a significant earnings increase, likely due to the recall's one-time costs and the company's growth trajectory. The wide gap between trailing and forward PE suggests that the market is pricing in a substantial recovery in earnings, which may be optimistic given the ongoing regulatory overhang.
PE
81.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 18x~294x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
38.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant. The company carries a debt-to-equity ratio of 0.69, indicating moderate leverage. While current assets cover liabilities 2.78x, the recall could lead to increased costs, potential lawsuits, and lower sales, straining cash flow. Trailing net income of $91.1M is thin relative to the $10.1B market cap, and the high trailing PE of 81x leaves no room for error. If the recall forces product replacements or refunds, profitability could be severely impacted, and the forward PE of 19.1x assumes a rapid earnings recovery that may not materialize.
FAQ
The primary risk is the FDA recall of Omnipod 5 pods, which could lead to market share loss, legal liabilities, and reputational damage. Financially, the company has moderate debt (debt-to-equity of 0.69) and thin net income, leaving little buffer for unexpected costs. Competitive risks include rivals like Tandem and Medtronic gaining ground. Macro risks include the stock's high beta of 1.08, making it sensitive to market swings. The most severe risk is a prolonged regulatory issue that could push the stock to its 52-week low of $126.40, a 14.3% drop from the current price.
The 12-month forecast is uncertain, with a base case probability of 50% for a price range of $145-$175, aligning with the analyst average target of $171.91. The bull case (25% probability) targets $200-$275, assuming successful recall resolution and strong growth. The bear case (25% probability) targets $126-$144, reflecting continued negative impacts. The most likely scenario is a slow recovery as the company manages the recall, but the outcome depends heavily on regulatory and competitive developments.
Based on trailing earnings, PODD is overvalued with a PE of 81x, but on forward earnings, it appears undervalued with a PE of 19.1x. This discrepancy reflects the market's expectation of a significant earnings recovery, likely due to the recall being a one-time event. Compared to the medical device industry average PE of around 25x, the forward PE is reasonable. However, the high trailing PE indicates that current earnings are insufficient to justify the price, making the stock vulnerable if the recovery fails to materialize.
PODD is not a good buy for risk-averse investors due to the ongoing FDA recall and significant downside risk. The stock is down 57.4% over the past year and trades near its 52-week low. While the average analyst target of $171.91 offers 16.6% upside, the low target of $144 implies further downside. For aggressive investors who believe the recall is a temporary setback, the stock could be a speculative buy, but only with a long-term horizon and acceptance of high volatility.
PODD is more suitable for long-term investors with a high risk tolerance, given the current regulatory uncertainty and high volatility (beta 1.08). Short-term trading is risky due to unpredictable news flow around the recall. The company's strong revenue growth and innovative product could support a recovery over 2-3 years, but the near-term outlook is clouded. A minimum holding period of 3-5 years is recommended to allow the company to resolve the recall and demonstrate sustained growth. Dividend income is not a factor, as the company pays no dividend.